HD Visual Learning
HD Visual Learning
Shared Decision-Making in Oncology
UV Exposure and Basal Cell Carcinoma: Genetic Mutations and Immune Suppression
Pathogenesis of Basal Cell Carcinoma (BCC)
Immunology and the Hedgehog Pathway in Basal Cell Carcinoma (BCC)
Best practices for assessment of HER2 expression in breast cancer *Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
HER2-directed ADCs: Adverse event recognition and management in patients with breast cancer *Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Shared Decision-Making in Oncology
Understanding Cell-free DNA (cfDNA)
*Supported by an educational grant from GRAIL, Inc.
Cancer Screening and Early Dection Test Accuracy
*Supported by an educational grant from GRAIL, Inc.
Understanding the Underlying Science of Current Cancer Screening
*Supported by an educational grant from GRAIL, Inc.
Discussing the Results of a Multicancer Early Detection Test
*Supported by an educational grant from GRAIL, Inc.
ICIs: Primary & Micrometastatic Disease
Tumorigenesis Cutaneous Squamous Cell Carcinoma (cSCC)
Shared Decision-Making in Oncology
Immune Dysfunction in Cutaneous Squamous Cell Carcinoma (cSCC)
Shared Decision-Making in Oncology
Targeting HER2: Updates on New and Emerging Treatment Approaches in Biliary Tract Cancers and Gastroesophageal Adenocarcinoma
*Supported by an independent medical educational grant from Jazz Pharmaceuticals.
Angiogenesis Overview
*Supported by an educational grant from Lilly.
Shared Decision-Making in Oncology
The Complement SystemÂ
*Supported by an educational grant from Novartis Pharmaceuticals Corporation.
PD1 and CTLA-4 Immune Checkpoints
Novel Immune Targets in Solid and Liquid Tumors
Shared Decision-Making in Oncology
Mechanistic Features of Bispecific Antibodies for Relapsed/Refractory NHL
Managing Adverse Events Associated with Bispecific Antibodies
Shared Decision-Making in Oncology
Considering ICI Therapeutic Combinations in Advanced Melanoma
Visualizing pathophysiologic processes
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
Developments of PD-L1 and LAG3 Combinations in Advanced Melanoma
Mechanisms of Bispecific Antibodies in Multiple Myeloma
Managing CRS and ICANS with Bispecific Antibodies
Shared Decision-Making in Oncology
Mechanisms of Resistance in Multiple Myeloma
Mechanisms of Therapies in Later-Line Multiple Myeloma Management *Supported by an educational grant from GlaxoSmithKline.
Rationale for ICIs in patients without targetable mutations, particularly patients with squamous cell NSCLC
MOA: Evaluating the mechanisms of checkpoint inhibition in NSCLC and relevant adverse events
Shared Decision-Making in Oncology
Mechanisms of HER2 Activation in NSCLC
*Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Adverse Events Associated With HER2-Directed ADCs for Advanced NSCLC: Presentation & Management
*Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Role of HER3 in EGFR-TKI resistance in Non-Small Cell Lung Cancer (NSCLC)
*Supported by an educational grant from Daiichi Sankyo.
TROP2 Cell-Aurface Antigen in Tumors and Tumorgenesis
*Supported by an educational grant from Daiichi Sankyo.
Modifying Chemotherapy Dosing in Pancreatic Cancer*Supported by an educational grant from Ipsen.
MOAs of HER2-directed ADCs for HER2-expressing solid tumors
*Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Development of AEs associated with the use of ADCs
*Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
ASH 2025: Myeloma BsAb iAR
Dive into immersive, case-based learning on evolving treatment strategies in multiple myeloma.This augmented reality experience is designed for hematology/oncology clinicians and provides highly interactive exploration of real-world decision-making in relapsed/refractory multiple myeloma (RRMM). Through two detailed patient cases, learners examine treatment sequencing, bispecific antibody (BsAb) integration, and toxicity management in accordance with clinical practice guidelines. Simply launch the app and point your device at a flat surface to begin. The AR experience places engaging, expert-informed content directly into the learner’s environment, supporting dynamic and personalized knowledge retention.
ESMO 2025: Shaping the Future of NMSC
This program discusses the management of NMSC
Non-melanoma skin cancers (NMSCs), including basal cell carcinoma and cutaneous squamous cell carcinoma, are typically managed with Mohs micrographic surgery, but advanced cases may require alternative approaches due to inoperability or progression. The immunogenicity of NMSCs makes them strong candidates for immune checkpoint inhibitor therapy, with agents like cemiplimab and pembrolizumab demonstrating favorable efficacy and tolerability. Emerging strategies, including neoadjuvant and intralesional immunotherapy, are under investigation to enhance tumor response prior to or in place of surgery. Continued development of these immunotherapeutic approaches offers the potential to improve outcomes in patient care.
Your Guide to Navigating Stage 4 (Metastatic) Melanoma: Treatment Options, Decision Making, & What to Expect
Your Guide to Navigating Non-Small Cell Lung Cancer Treatment, Adherence & What to Expect
Understanding Gastroesophageal Adenocarcinoma (GEA) and Biliary Tract Cancer (BTC) *Supported by an independent medical education grant from Jazz Pharmaceuticals.
Preventing and Treating Blood Clots:
A Guide to Patients with Cancer *Supported by an educational grant from Bristol Myers Squibb.
Patient Resources and Tools for Immunotherapy and Immune-Related Adverse Events *Supported by an educational grant from Merck & Co.
NHL (DLBCL): A progressive case study
Management of Recurrent Stage 2 cSCC and Rationale for Treatment
Management Pearls for Treatment of Multiple Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Treatment Strategies for Relapsed/Refractory Multiple Myeloma
NSCLC – Shared Decision Making Case Study
The ASH 2025 ENCOMPASS Experience: Advancing BCMA-Directed Bispecific Antibodies in r/rMM: Mechanistic Rationale, Clinical Evidence & Strategies to Optimize Patient Outcomes
Virtual Booth